CHUGAI PHARMACEUTICAL CO., LTD.

Home > Investor Relations > Reports & Downloads > Development Pipeline

Development Pipeline

Oncology

Development code
(Compound number)
Indication
# Additional
indication
Stage
(date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
RG3502
(RO5304020)
Breast cancer Launched
(14/04)
trastuzumab emtansine
Kadcyla®
Injection
Roche
Kadcyla®
Anti-HER2 antibody-tubulin polymerization inhibitor conjugate
Breast cancer (adjuvant) # Phase III
Multinational study
Gastric cancer # Phase II / III
Multinational study
AF802/RG7853
(CH5424802/
RO5424802)
Non-small cell lung cancer Approved
(14/07)
alectinib
Alecensa®
Oral
In-house

(Roche)
ALK inhibitor
Phase I / II
Overseas
RG7204
(RO5185426)
Melanoma Filed
(14/04)
vemurafenib

Oral
Roche
Zelboraf®
BRAF inhibitor
RG1273
(RO4368451)
Breast cancer (adjuvant) # Phase III
Multinational study
pertuzumab
Perjeta®
Injection
Roche
Perjeta®
HER2 dimerization inhibitory humanized monoclonal antibody
Gastric cancer # Phase III
Multinational study
GA101/RG7159
(RO5072759)
Indolent non-Hodgikin’s lymphoma (NHL) Phase III
Multinational study
obinutuzumab
 
Injection
Roche
Gazyva®
(Nippon Shinyaku)
Glycoengineered type II anti-CD20 monoclonal antibody
Aggressive NHL Phase III
Multinational study
RG7446
(MPDL3280A)
Non-small cell lung cancer Phase III
Multinational study


Injection
Roche Engineered anti-PDL1 monoclonal antibody
GC33/RG7686
(GC33/
RO5137382)
Hepatocellular carcinoma Phase II
Multinational study
 
 
Injection
In-house

(Roche)
Anti-Glypican-3 humanized monoclonal antibody
RG340
(Ro09-1978)
Gastric cancer (adjuvant) # Phase II capecitabine
Xeloda®
Oral
Roche
Xeloda®
(Yakult Honsha)
Antimetabolite, 5-FU derivative
CKI27/RG7304
(RO5126766)
Solid tumors Phase I

Oral
In-house

(Roche)
Raf and MEK dual inhibitor
Phase I
Overseas
RG7321
(GDC-0941)
Solid tumors Phase I pictilisib

Oral
Roche PI3K inhibitor
RG7596
(RO5541077)
NHL Phase I polatuzumab vedotin
 
Injection
Roche Anti-CD79b antibody-drug conjugate
RG435
(RO4876646)
Breast cancer (adjuvant) # Development
Discontinued
bevacizumab
Avastin®
Injection
Roche
Avastin®
Anti-VEGF (Vascular Endothelial Growth Factor) humanized monoclonal antibody

Bone and Joint Diseases

Development code
(Compound number)
Indication
# Additional
indication
Stage
(date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
RG484
(Ro200-5450po)
Osteoporosis Phase III ibandronic acid
Bonviva®
Oral
Roche
Boniva® (US) / Bonviva® (EU)
(Taisho Pharmaceutical)
Bisphosphonate
NRD101
(NRD101)
Enthesopathy
(Lateral epicondylitis, Patellar tendinitis,
Achilles tendinopathy, Plantar fasciitis) #
Phase III sodium hyaluronate
Suvenyl®
Injection
In-house Sodium hyaluronate

Autoimmune Diseases

Development code
(Compound number)
Indication
# Additional
indication
Stage
(date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
MRA
(RO4877533)
Rheumatoid arthritis (new formulation: subcutaneous injection) Approved
(14/04)
EU
tocilizumab
Actemra® / RoActemra® (EU)
Injection
In-house

(Roche)
Humanized anti-human IL-6 receptor monoclonal antibody
Giant cell arteritis # Phase III
Overseas
Systemic sclerosis # Phase II
Overseas
SA237
(SA237)
Neuromyelitis optica (NMO) Phase III
Multinational study*


Injection
In-house Anti-IL-6 receptor humanized monoclonal antibody
RG7415
(PRO155767)
Systemic lupus erythematosus (SLE) Development
Discontinued
rontalizumab

Injection
Roche Anti-interferon alpha humanized monoclonal antibody

* Multinational study managed by Chugai

Central Nervous System

Development code
(Compound number)
Indication
# Additional
indication
Stage
(date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
RG1678
(RO4917838)
Schizophrenia Phase III
Multinational study
bitopertin

Oral
Roche Glycine reuptake inhibitor
RG1450
(RO4909832)
Alzheimer’s disease Phase III
Multinational study
gantenerumab

Injection
Roche / MorphoSys Anti-amyloid-beta human monoclonal antibody
RG7090
(RO4917523)
Major depressive disorder Phase II
Multinational study
basimglurant

Oral
Roche mGluR5 antagonist
RG1577
(RO4602522)
Alzheimer’s disease Phase I

Oral
Roche MAO-B inhibitor
RG1662
(RO5186582)
Improvement of intellectual ability in individuals with Down syndrome Phase I

Oral
Roche GABAAα5 receptor antagonist

Respiratory Diseases

Development code
(Compound number)
Indication
# Additional
indication
Stage
(date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
RG3637
(RO5490255)
Asthma Phase III
Multinational study
lebrikizumab
 
Injection
Roche Anti-IL-13 humanized monoclonal antibody

Others

Development code
(Compound number)
Indication
# Additional
indication
Stage
(date)
Generic name
Product name
Dosage form
Origin
Overseas name
(Collaborator)
Mode of Action
CIM331
(CIM331)
Atopic dermatitis Phase II
Multinational study*
 
 
Injection
In-house Anti-IL-31 receptor humanized monoclonal antibody
ACE910 / RG6013
(ACE910)
Hemophilia A Phase I / II  
 
Injection
In-house Anti-factor IXa × anti-factor X humanized bispecific antibody
URC102
(URC102)
Gout Phase I
Overseas
 
 
Oral
In-house

(JW Pharmaceutical)
URAT1 inhibitor
RG7652 Hyperlipidemia Development
Discontinued
 
 
Injection
Roche Anti-PCSK9 human monoclonal antibody

* Multinational study managed by Chugai

To view PDF files,
you will need Adobe® Reader® which is available as a free download.